BW 20805
Alternative Names: BW-20805; PKK siRNALatest Information Update: 04 Mar 2024
Price :
$50 *
At a glance
- Originator Argo Biopharma
- Class Skin disorder therapies; Small interfering RNA; Vascular disorder therapies
- Mechanism of Action Plasma kallikrein expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Hereditary angioedema
Most Recent Events
- 21 Feb 2024 BW 20805 is available for licensing as of 21 Feb 2024. https://www.argobiopharma.com/pipeline/index.html (Argo Biopharma pipeline, February 2024)
- 04 Aug 2023 Phase-I clinical trials in Hereditary angioedema (In adults, In volunteers) in Australia (SC) (ACTRN12623000689673)
- 03 Aug 2023 Argo Biopharma has patent protection covering "Compositions and methods for inhibiting expression of prekallikrein (pkk) protein" worldwide